Explore FREE downloadable educational materials.
What is COVID-19 vaccine?
Coronaviruses are a group of diverse, single-stranded, enveloped RNA viruses that cause a wide range of respiratory, gastrointestinal and neurologic illnesses with varying severity in animals and humans. Most coronaviruses, including those causing the common cold, are not associated with significant mortality, with the exception of Severe Acute Respiratory Syndrome (SARS), which emerged in China in 2002, the coronavirus causing Middle East Respiratory Syndrome (MERS), which was identified in Jordan and Saudi Arabia in 2012, and SARS-CoV-2, new novel coronavirus, which was initially identified in Wuhan City, in the Hubei province of China. In the U.S., there are no FDA-licensed vaccines targeting SARS, MERS or any of the four common coronaviruses.
Immediately after the January 30, 2020 WHO declaration that a novel coronavirus outbreak in China posed a “public health emergency of international concern,” the Gates Foundation and World Health Organization (WHO) issued press releases informing the world that experimental coronavirus vaccines already in development would be put on a fast track to licensure for global use.
In May 2020, Former President Donald Trump announced the rollout of Operation Warp Speed, a plan to develop, manufacture, and distribute millions of COVID-19 vaccine doses by the end of 2020. According to the National Institute of Allergy and Infectious Diseases (NIAID):
“Operation Warp Speed is a partnership among several federal government agencies to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics, including the specific goal of delivering 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.
Notably, Operation Warp Speed will manufacture promising candidate vaccines at an industrial scale before efficacy and safety are confirmed through Phase III trials. Doing so will significantly shorten the timeline for distribution as compared to traditional vaccine development, should the trials succeed.”
New ways to make vaccines including new technologies and production platforms quickly became favored over the older traditional ways to make vaccines in the COVID-19 vaccine race.
Traditional vaccines contain attenuated (live) or inactivated (killed) viruses or bacteria or selected proteins, as well as adjuvants, such as aluminum, to stimulate an immune response that produces artificial immunity. For example, older viral vaccines for smallpox and measles vaccine contain live attenuated viruses; injectable influenza vaccines contain inactivated viruses; the recombinant hepatitis B virus vaccine is a protein subunit vaccine, while the newer human papillomavirus (HPV) virus vaccine contains virus-like particles.
For the past two decades, researchers have been experimenting with gene-based technology platforms, notably ones that introduce foreign DNA and RNA into cells of the body, to develop experimental vaccines for SARS, MERS, HIV and other diseases.
Table of Contents
- Pre-licensing Clinical Trial Process
- Emergency Use Authorization
- Pfizer - BioNTech mRNA COVID-19 Vaccine Approval
- Moderna mRNA COVID-19 Vaccine
- Janssen/Johnson & Johnson COVID-19 Viral Vector Vaccine
- Additional COVID-19 Vaccines
- AstraZeneca-University of Oxford Viral Vector COVID-19 vaccine
- Inovio Pharmaceuticals INO-4800 DNA Vaccine
- Novavax COVID-19 Vaccine
Pre-licensing Clinical Trial Process
According to the U.S Food and Drug Administration (FDA), pre-licensing clinical trials are generally conducted in three phases. Phase 1 trials are the initial human studies involving a small number of individuals to test for safety and immune response. Phase 2 studies usually enroll a slightly larger number of subjects and focuses on selecting the product’s dosage. The final pre-licensing study, Phase 3, collects data on the experimental product’s effectiveness and safety. The FDA reports that Phase 3 trials typically involve thousands of subjects.
Double-blind, randomized, placebo-controlled trials (RCTs) are considered the most reliable research method. In these studies, one group of subjects receives the experimental product being tested while the other group receives a placebo designed to appear as similar as possible to the product being studied. Individuals in both groups do not know whether they are receiving the experimental product or the placebo. Additionally, the researchers conducting the trials are also not made aware about which group is receiving which treatment (making it a "double-blind" experiment). This is important, as it prevents the researchers from unconsciously biasing their evaluation of the results or unintentionally tipping off the study participants.
If pre-licensing clinical trials are considered successful, the manufacturer can submit a Biologics License Application (BLA). This application must include safety and efficacy data and contain enough information to allow the FDA review team to decide on whether to approve or deny a vaccine. Once the application is reviewed by the FDA, the manufacturer along with the FDA may present their information to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). This committee is comprised of non-FDA scientists, physicians and others whose charge is to provide advice to the FDA on the data provided in a public forum. The FDA, however, has the option to disregard any feedback it receives from VRBPAC.
Typically, it takes several years, if not decades, for pharmaceutical companies to develop, test, and receive approval for a new vaccine. The fastest timeline to date for a vaccine to complete all stages of clinical development, pre-licensing clinical trials and FDA-approval has been four years.
On June 30, 2020, the FDA announced that a COVID-19 vaccine would only receive approval, if it were at least 50 percent more effective than a placebo at either preventing illness or reducing its severity.
The FDA released its guidance for industry regarding Emergency Use Authorization (EUA) approval for COVID-19 vaccines on October 6, 2020, and stated that it would be requiring that at least half of all Phase 3 clinical trial participants be followed for at least two months following administration of the second vaccine dose. The FDA also requested that vaccine manufacturers submit information on a minimum of five cases of severe COVID-19 disease among individuals who received the placebo.
However, vaccine trial designs have faced criticism and in October of 2020 the British Medical Journal (BMJ) noted that Phase 3 trials for Moderna, Pfizer, AstraZeneca COVID-19 vaccines will not answer basic questions around preventing infection and reducing the likelihood of severe illness.
A September 2020 article in Forbes by noted biologist William Haseltine, PhD revealed that COVID-19 vaccine studies by Moderna, Pfizer, AstraZeneca and Johnson & Johnson intend “to complete interim and primary analyses that at most include 164 participants.”
According to Dr. Haseltine, with an efficacy success requirement of 70 percent, this equates to interim analysis based on the results of infection ranging from 32 (Moderna) vaccine to 77 (Johnson & Johnson) vaccine recipients. Dr. Haseltine concluded by saying that COVID-19 vaccine trials were in essence designed to succeed. The article also contained many of the same concerns noted in the October 2020 BMJ article and added that “vaccines currently under trial will not be the silver bullet” ending the pandemic.
Emergency Use Authorization
According to the FDA, vaccine makers may submit an application to have their products approved under an Emergency Use Authorization (EUA). Under EUA authority, the FDA Commissioner may permit “unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN (CBRN = chemical, biological, radiological, nuclear) threat agents when there are no adequate, approved, and available alternatives.” To learn more about EUA products and vaccines and consumer rights, visit NVIC’s FAQ on Emergency Use Vaccines (EUA) & Vaccine Injury Compensation.
In December 2020, two experimental messenger RNA COVID-19 vaccines developed and produced by Pfizer - BioNTech and Moderna with NIAID had been granted an EUA by the FDA to release the vaccines for use in the U.S. Messenger RNA (mRNA) vaccines are gene based vaccines that involve injecting lipid nanoparticles containing mRNA (genetic code) that enable the vaccine to get past the cell wall, into the intracellular space, then causes the cell’s ribosome to make viral proteins (antigen that stimulate the immune system.) In essence, an mRNA vaccine tricks the body into producing the viral proteins to trigger an immune response. Messenger RNA vaccines can be produced in the lab using faster and less expensive processes than traditional vaccines.
On February 27, 2021, the FDA granted an Emergency Use Authorization to Johnson & Johnson and Janssen Pharmaceutical Companies for a non-replicating viral vaccine. This experimental vaccine uses an adaption of human adenovirus 26 (Ad26), which causes common colds, to transport the SARS-CoV-2 spike protein code into the body to trigger an immune response.
Pfizer - BioNTech mRNA COVID-19 Vaccine Approval
On August 23, 2021 the FDA licensed and granted EUA status to Comirnaty COVID-19 vaccine, an mRNA vaccine developed BioNTech, for use in persons 16 years of age and older. The FDA also stated that use of Comirnaty and the experimental Pfizer-BioNTech mRNA COVID-19 vaccine are interchangeable due to having the same formulation. However, the FDA also stated that the Pfizer-BioNTech experimental vaccine and the BLA approved Comirnaty were legally distinct, but did not disclose how and why the two vaccines are legally distinct. As of October 20, 2021 the FDA has now stated that the “vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty”.
Following FDA approval of Comirnaty in August 2021, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of the 2-dose vaccine series in persons 16 years of age and older.
When a product receives a priority review designation by the FDA, the decision to take action on the application is usually done within 6 months. In the case of the Pfizer – BioNTech vaccine, the decision to grant full approval was completed in less than four months.
Prior to granting approval of Comirnaty, the FDA declined to hold a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting despite previously stating that they were “committed to use an advisory committee composed of independent experts to ensure deliberations about authorization or licensure are transparent for the public.”
In the Summary Basis for Regulatory Action Document published to support approval of Comirnaty, the FDA reported that it “did not refer this application to the VRBPAC because our review of the information submitted to this BLA did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.”
The Pfizer-BioNTech mRNA COVID-19 vaccine was initially issued an EUA by the FDA on December 11, 2020 for use in persons 16 years of age and older. The FDA expanded the EUA to include adolescents 12 and older on May 10, 2021.
According to the Fact Sheet provided by the FDA, the Comirnaty /Pfizer-BioNTech COVID-19 Vaccine is manufactured and made available as a frozen suspension in vials that contain multiple doses. Each individual vial must be diluted with 1.8 ml of sterile 0.9 percent Sodium Chloride injection, USP, before use.
Each dose contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) that encodes the viral spike (S) glycoprotein of SARS-CoV-2. Additional vaccine ingredients include lipids (0.43 mg (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000- N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol), 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.01 mg potassium chloride, 6 mg sucrose, and 0.07 mg dibasic sodium phosphate dihydrate. The 0.9 percent Sodium Chloride Injection, USP adds another 2.16 mg sodium chloride per dose.
This vaccine does not contain a preservative and the vaccine vial stoppers are free of latex.
Additionally, the Comirnaty/Pfizer-BioNTech Fact Sheet states:
“The modRNA in the Pfizer-BioNTech COVID-19 Vaccine is formulated in lipid particles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.”
The Comirnaty/Pfizer-BioNTech COVID-19 Vaccine is recommended to be given intramuscularly (IM) as a two-dose series administered three weeks apart. There is no available data on the interchangeability of the Comirnaty/Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the two-dose vaccination series. Persons who have received one dose of Comirnaty/Pfizer-BioNTech COVID-19 Vaccine should complete the series by receiving a second dose of Comirnaty/Pfizer-BioNTech COVID-19 Vaccine.
There is no data available on the co-administration of the Comirnaty/Pfizer-BioNTech Vaccine with any other vaccine product.
The duration of vaccine-acquired immunity from Pfizer-BioNTech’s COVID-19 vaccine is not known. It is also not known whether this vaccine can reduce or stop transmission of the virus. This means that vaccinated individuals may still be capable of transmitting the virus to others.
There is insufficient data to support the use of Pfizer-BioNTech’s COVID-19 vaccine in persons who are positive for SARS-CoV-2 at the time of vaccination. In clinical trials, there was one case of COVID-19 illness in both the vaccine group and the placebo group in persons who were found to be positive for SARS-CoV-2 at baseline. Based on the limited data of this sub-population provided to the FDA by Pfizer-BioNTech, the vaccine efficacy in this population was reported at -7.1 percent (Confidence Ratio -8309.9, 98.6).
The Pfizer-BioNTech COVID-19 vaccine is recommended to be shipped and stored between -80ºC to -60ºC (-112ºF to -76ºF) and protected from light until ready to use. On February 25, 2021, the FDA announced that frozen undiluted vials of the Pfizer-BioNTech COVID-19 could also be transported and stored at temperatures typically found in pharmaceutical freezers for up to 14 days. Temperature storage and shipping guidelines were updated again on May 19, 2021, which permitted undiluted, thawed vaccines to be stored at refrigerator temperatures, 2°C to 8°C (35°F to 46°F), for up to 1 month.
Mishandling of the vaccine during any step of the distribution process may result in an ineffective vaccine product.
The CDC reports that six months after two doses of Pfizer-BioNTech COVID-19 vaccine, the efficacy in preventing disease is 91.1 percent in persons 16 and older. Pfizer-BioNTech reports that the vaccine is just as effective against the U.K.’s B.1.1.7 (Alpha) as the earlier variant of SARS-CoV-2 virus. The vaccine, however, appears to be less effective against the South African B.1.351 (Beta) variant.
In June 2021, Israeli health officials report the Pfizer-BioNTech COVID-19 vaccine to be 64 percent effective against the SARS-CoV-2 variant B.1.617 (Delta). Pfizer company officials have acknowledged waning effectiveness of two doses of the vaccine against this variant. By late July 2021, the vaccine was reported to be only 39 percent effective in Israel; however Israeli health officials report the vaccine to be 88 percent effective against hospitalization and 91 percent effective against death.
According to a pre-peer review study conducted by researchers from the Mayo Clinic and nference, a data analytics company, by July 2021, the Pfizer-BioNTech COVID-19 vaccine was reported to be only 42 percent.
On August 12, 2021, the FDA authorized use of an additional (third) dose of Pfizer-BioNTech COVID-19 vaccine in persons with certain immunosuppressive conditions, such as solid organ transplant recipients and individuals with similar conditions.
The FDA’s Vaccine and Related Biologicals Products Advisory Committee (VRBPAC) voted on September 17, 2021 to authorize use of a booster dose under EUA in persons 65 years and older and for those at high risk of severe COVID-19 disease. The third dose is recommended to be administered six months following the second dose. According to data released from Pfizer officials in advance of the September 17th VRBPAC meeting, the mRNA vaccine waned by 6 percent each month following administration of the second dose and by 6 to 8 months, offered limited protection.
The FDA amended the Pfizer-BioNTech EUA on September 22, 2021 and authorized a booster dose in all persons 65 years and older, in individuals 50 through 64 years at high risk for COVID-19, and in persons 18 through 64 “whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.”
While the CDC’s ACIP voted on September 23, 2021 to recommend booster doses in all persons 65 and older, in persons 50 through 64 years with pre-existing health conditions that put them at increased risk from COVID-19 infection, and in persons 18 through 49 who are at risk of infection due to pre-existing health conditions based on an individual’s personal risk/benefits, they voted against recommending a booster dose for all persons 18 through 64 years whose living or employment situation places them at high risk for COVID-19 infection. CDC Director Dr. Rochelle Walensky, however, overruled ACIP and went ahead and issued a recommendation for a booster dose of Pfizer-BioNTech COVID-19 vaccine in all persons 18 and older who work or live in high-risk settings.
The use of booster doses has been criticized by WHO as well as those within the medical community. WHO has expressed disapproval of the White House booster dose plan and questioned the ethics of administering additional doses to Americans prior to ensuring that initial doses are given to persons globally.
Moderna mRNA COVID-19 Vaccine
On December 18, 2020, the FDA issued an EUA for Moderna’s experimental mRNA COVID-19 Vaccine for use in persons 18 years of age and older.
According to the Fact Sheet provided by the FDA, each 0.5 ml dose of Moderna’s COVID-19 Vaccine contains 100 mcg of nucleoside modified messenger RNA (mRNA) that encodes the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Each dose also contains a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG 2000 dimyristoyl glycerol [DMG, cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC), 0.31 mg tromethamine, 0.043 mg acetic acid, 1.18 mg tromethamine hydrochloride, 43.5 mg sucrose and 0.12 mg sodium acetate. This vaccine does not contain a preservative and the vaccine vial stoppers are free of latex.
Additionally, the Moderna Fact Sheet states:
“The nucleoside-modified mRNA in the Moderna COVID-19 Vaccine is formulated in lipid particles, which enable delivery of the nucleoside-modified mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.”
The Moderna COVID-19 Vaccine is recommended to be given as a two-dose series administered 28 days apart. There is no available data available on the interchangeability of the Moderna COVID-19 Vaccine with other COVID-19 vaccines to complete the two-dose vaccination series. Persons who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.
The duration of vaccine-acquired immunity from Moderna’s COVID-19 vaccine is not known. It is also not known whether this vaccine can reduce or stop transmission of the virus. This means that vaccinated individuals may still be capable of transmitting the virus to others.
There is insufficient data on the use of Moderna’s COVID-19 vaccine in persons who are positive for SARS-CoV-2 at baseline. In clinical trials, there were no cases of COVID-19 illness in persons who were determined to be positive for SARS-CoV-2 at baseline in the vaccine group, and only one case among the SARS-CoV-2 positive individuals at baseline who were part of the placebo group.
The CDC states vaccine efficacy for the Moderna is 94.1 percent. Moderna reports that its COVID-19 vaccine appears to offer vaccine-acquired protection against the U.K’s B.1.1.7 (Alpha) variant. The vaccine, however, had a six-fold reduction against the South African B.1.351 (Beta) variant when compared to the initial SARS-CoV-2 virus.
According to a pre-peer review study conducted by researchers from the Mayo Clinic and nference, a data analytics company, by July 2021, the Moderna COVID-19 vaccine was reported to be only 76 percent.
On August 12, 2021, the FDA authorized use of an additional (third) dose of Moderna COVID-19 vaccine in persons with certain immunosuppressive conditions, such as solid organ transplant recipients and individuals with similar conditions.
Leading health officials have reported that review of the application to support the use of a third Moderna vaccine dose would likely not be completed prior to the White House’s September 20th timeline to begin administration of the additional dose. According to health officials, data submitted to the FDA as of September 1, 2021 was “found inadequate and needs strengthening.”
As of September 27, 2021, the CDC is reporting that persons who have received a primary series of the Moderna COVID-19 vaccine will likely need a booster dose and that data on the safety and effectiveness of a booster dose is expected in the near future.
Janssen/Johnson & Johnson COVID-19 Viral Vector Vaccine
Viral vector vaccines genetically engineer live viruses such as poxviruses and adenoviruses to include the SARS-CoV-2 spike protein code. The engineered viruses are then used as a vector, or delivery method, to get the altered genetic code inside the cell where the cell’s ribosome produces SARS-CoV-2 protein antigen that is recognized by immune system to elicit a protective immune response.
On February 27, 2021, the FDA issued an EUA for Janssen/Johnson & Johnson’s experimental vaccine for use in persons 18 years of age and older.
Janssen/Johnson & Johnson’s experimental vaccine, Ad26.COV2.S, is a non-replicating viral vector vaccine that uses AdVac® and PER.C6® technologies. AdVac technology uses an adaptation of human Adenovirus 26 to transport the genetic code of the SARS-CoV-2 spike protein into the body to trigger an immune response. PER.C6 are proprietary cells owned by Janssen Pharmaceutical Companies that were developed in 1985 from retinal cells of an 18-week-old aborted fetus.
Adenoviruses are “non-enveloped, double-stranded DNA viruses” that often cause mild respiratory or gastrointestinal infections like the common cold in humans; however, an adenovirus infection can be serious in persons with a compromised immune system or pre-existing respiratory or cardiac issues.
Several characteristics are considered as advantages to using an adenoviral vector for delivering a vaccine antigen, including the ability to stimulate both an innate (cell-mediated) and humoral (adaptive) immune system response and because adenoviral vectored vaccines are easy to genetically manipulate. Another feature is that the adenovirus itself can trigger the vaccine’s inflammatory immune response. This means that it is not necessary to add an adjuvant to the vaccine to provoke an inflammatory response to stimulates immunity.
Each 0.5 mL dose of the vaccine also contains citric acid monohydrate (0.14 mg), ethanol (2.04 mg), trisodium citrate dihydrate (2.02 mg), 2-hydroxypropyl-β-cyclodextrin (HBCD) (25.50 mg), polysorbate-80 (0.16 mg), and sodium chloride (2.19 mg). Additionally, each dose may also contain residual amounts of host cell DNA host and/or cell proteins. This vaccine does not contain a preservative and the vaccine vial stoppers are free of latex. The vaccine is approved to be administered as a single 0.5mL dose intramuscularly.
In clinical trials, the vaccine was 66.9 percent effective in preventing moderate to severe COVID-19 occurring at least 14 days after vaccination and 66.1 percent effective in preventing moderate to severe COVID-19 occurring at least 28 days after vaccination. The vaccine, however, was reported to be only 42 percent effective in persons over the age of 60 who have underlying health conditions. As of September 27, 2021, the CDC continues to reported that preliminary data suggests the vaccine has an overall efficacy of 66.3 percent.
On April 13, 2021, the FDA and CDC paused use of the Janssen/Johnson & Johnson vaccine after serious blood clots were reported in women between the ages of 18 and 49. By April 23, 2021, 15 cases and 3 deaths had been associated with the rare blood clot disorder, now referred to by health officials as thrombosis with thrombocytopenia syndrome (TTS). All cases were reported in women, with 2 occurring in women over 50 years of age. The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to resume full use of the vaccine in all persons 18 years of age and older on April 23, 2021, by a vote of 10 to 4 (with one voting member abstaining due to a conflict of interest). Those who voted against the recommendation expressed concern regarding the lack of warning on the risk of TTS in women under 50 years of age.
By May 7, 2021, there had been 28 cases of TTS and 3 deaths confirmed by the CDC to be related to the Johnson & Johnson/Janssen COVID-19 vaccine. Additionally, TTS has been reported in men and in women between 50 and 60, in addition to women between 18 and 49 years.
On July 13, 2021, Janssen/Johnson & Johnson company officials reported that they were working on modifying their COVID-19 vaccine in an attempt to reduce or eliminate the risk of blood clots.
As of October 6, 2021, 47 cases of TTS following the Janssen/Johnson & Johnson COVID-19 vaccine had been confirmed by the CDC and FDA.
Additionally, on July 13, 2021, the FDA announced revisions to the Fact Sheet for Healthcare Providers Administering the Johnson & Johnson/Janssen COVID-19 vaccine and the Fact Sheet for Recipients and Caregivers to include information regarding an increased risk of Guillain-Barré Syndrome (GBS) following vaccination. GBS, a serious neurological disorder where the body’s immune system attacks the peripheral nervous system, can cause muscle weakness, paralysis, and even death. According to the press release, the FDA reported 100 cases of GBS following vaccination, with 95 considered serious and requiring hospitalization, and one death. Government health officials noted that there was insufficient evidence to establish a causal relationship between the Johnson & Johnson/Janssen COVID-19 vaccine and GBS, and reported that “the known and potential benefits clearly outweigh the known and potential risks.”
As of October 6, 2021, 228 cases of GBS following the Janssen/Johnson & Johnson COVID-19 had been identified in the VAERS data. According to the CDC, most cases occurred within 2 weeks of vaccination and among men, primarily those aged 50 and older.
Additional COVID-19 Vaccines
Although several COVID-19 vaccine candidates employ unproven vaccine technologies, many COVID-19 vaccines that employ traditional vaccine manufacturing methods are under development and in pre-licensure clinical trials. These include several experimental inactivated vaccine candidates by Chinese based pharmaceutical companies.
Globally, 320 COVID-19 vaccines are under development and as of October 15, 2021, 126 experimental vaccines were in clinical trials.
AstraZeneca-University of Oxford Viral Vector COVID-19 vaccine
A development team from the University of Oxford in the United Kingdom endeavored to make an experimental COVID-19 vaccine candidate by the end of the summer of 2020. Teaming with AstraZeneca in April of 2020 to develop, manufacture, and distribute the ChAdOx1 nCoV-19 vaccine (now referred to as AZD1222) in the U.S., this COVID-19 vaccine candidate is a non-replicating viral vector vaccine that uses a chimpanzee adenovirus to express the SARS-CoV-2 protein. According to the University of Oxford:
“Genetic material has been added to the ChAdOx1 construct, that is used to make proteins from the COVID-19 virus (SARS-CoV-2) called Spike glycoprotein (S). This protein is usually found on the surface of SARS-CoV-2 and plays an essential role in the infection pathway of the SARS-CoV-2 virus. The SARS-CoV-2 coronavirus uses its spike protein to bind to ACE2 receptors on human cells to gain entry to the cells and cause an infection.”
The University of Oxford reported that the initial clinical trials of ChAdOx1 nCoV-19 would involve 800 individuals. Half would receive the experimental vaccine while the other half would serve as the control group and receive a meningitis vaccine (MenACWY).
In July 2020, preliminary results of the AstraZeneca’s Phase 1 and Phase 2 trials were published in The Lancet. This study involved 1,077 healthy adults between 18 and 55 years of age who were randomly given either the ChAdOx1 nCoV-19 vaccine (AZD1222) or the meningococcal conjugate (MenACWY) vaccine. Systemic and local reactions were more common in the trial group given the experimental COVID-19 vaccine, and a selection of participants from both groups received prophylactic paracetamol (acetaminophen) before vaccinations were administered.
Headache and fatigue were the most commonly reported systemic reactions. Headaches were reported in the experimental COVID-19 vaccine group by 68 percent of the participants without acetaminophen and 61 percent with acetaminophen and in the MenACWY group by 41 percent of the participants without acetaminophen and 37 percent of the participants with acetaminophen. Fatigue was reported in the experimental COVID-19 vaccine group by 70 percent of the participants, who were not give acetaminophen prior to vaccination, and in the MenACWY group by 48 percent of the participants without acetaminophen.
Other common systemic adverse reactions reported in the experimental COVID-19 vaccine group included feeling feverish (51 percent), chills (56 percent), muscle ache (60 percent) and malaise (61 percent). Eighteen percent of participants who did not receive acetaminophen and 16 percent of participants who did reported a temperature of at least 100.4°F. Two percent of patients without acetaminophen reported a temperature of at least 102.2°F. In comparison, less than one percent of individuals receiving MenACWY reported a fever of at least 100.4°F, none of whom were receiving prophylactic acetaminophen. The intensity and severity of systemic and local reactions was highest on the first day after vaccination.
Phase 3 clinical trials began in late August 2020. Their goal was to enroll 30,000 vaccine participants through 62 sites. On September 8, 2020, the pharmaceutical company announced that it was putting the trial on hold after a female participant in the U.K. developed transverse myelitis, a rare but serious neurological disorder, which causes inflammation of the spinal cord.
This was the second time that AZD1222 vaccine trials were placed on hold. In July 2020, trials were paused after a woman developed multiple sclerosis; however, company officials reported that her diagnosis was not related to vaccination.
While clinical trials resumed quickly in several countries including Great Britain, Japan, South Africa, India, and Canada, trials in the U.S. remained on hold until October 23, 2020.
On October 1, 2020, the European Medicines Agency (EMA) stated that it had started reviewing AstraZeneca’s COVID-19 clinical trial data in real time, and anticipated that following approval, all adults in Britain could receive at least one vaccine dose within 6 months.
Trials in the U.S. involving the University of Oxford and AstraZeneca’s experimental COVID-19 vaccine candidate were put on hold in early September 2020 due to safety concerns. While several countries including Canada, Japan, Brazil, South Africa, and Great Britain continued with clinical trials despite these concerns, U.S trials did not resume until October 23, 2020. According to the Wall Street Journal, the FDA did not fault the vaccine for the serious neurological events that occurred in two trial participants, however, they have not yet ruled out a link.
At the January 27, 2021 ACIP meeting, company officials from AstraZeneca reported that across the four studies, serious adverse events occurred in 168 participants, with 79 occurring among persons who received the experimental COVID-19 vaccine, and 89 among persons who received either the MenACWY vaccine or saline control. In total, 175 serious adverse events were reported; however, only four events were considered as possibly related to vaccination by clinical trial investigators. In the COVID-19 vaccine group, one participant experienced a high fever two days following the first vaccine dose that resolved with paracetamol (acetaminophen) treatment on the same day and another participant developed transverse myelitis two weeks after the second vaccine dose. In the control group, one participant developed autoimmune hemolytic anemia ten days after MenACWY, and another participant developed transverse myelitis two months after the first control dose.
AstraZeneca company officials reported that most solicited adverse events were mild to moderate and the majority resolved within a few days of vaccination. The most commonly reported adverse events included injection site tenderness, injection site pain, fatigue, headache, muscle and joint pain, malaise, fever, chills, and nausea. Adverse events were more common after the first vaccine dose.
On January 29, 2021, the European Union approved the vaccine for use in individuals 18 years and older despite limited data to support its effectiveness in adults over the age 55 years. The University of Oxford and AstraZeneca’s experimental COVID-19 vaccine is estimated to have an efficacy of about 60 percent. Health officials in Germany, however, are not recommending use of the vaccine in adults 65 years of age and older after concluding that there was not enough data to determine whether the vaccine was effective in this population.
Health officials in South Africa halted use of the AstraZeneca COVID-19 vaccine in February 2021, after it was found to be less than 25 percent effective against the B.1.351 (Beta) variant, which is most common SARS-CoV-2 virus variant circulating in South Africa and has been detected in most U.S. states.
On March 12, 2021, CNN reported that while AstraZeneca, and UK and European regulators stated there was no evidence of this experimental COVID-19 vaccine causing blood clots, a number of countries had already suspended use of the vaccine. These countries included Denmark, Norway, Iceland, and Thailand. Other countries, like Austria and Italy chose instead to suspend specific batches of the vaccine, while Spain delayed rollout of the AstraZeneca vaccine. On June 11, 2021, Italy suspended use of the vaccine in persons under 60 years following the death of an 18-year-old female from cerebral hemorrhage 16 days post vaccination.
The World Health Organization (WHO) issued a statement on March 19, 2021 stating that their Global Advisory Committee on Vaccine Safety reviewed data on the vaccine in relation to blood clots and low platelets after vaccination and concluded that the rates of these events are fewer than when they occur naturally in the generalized population. The WHO added and that these events would continue to be monitored.
Soon thereafter, Canadian health officials joined France and limited the vaccine’s use in persons under 55 years of age, stating “From what is known at this time, there is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccine to adults under 55 years of age,” and had requested a new risk analysis on the vaccine’s risks and benefits broken down by age and gender. On March 30, 2021, Germany limited its use to persons over the age of 60.
On April 7, 2021, the European Medicines Agency (EMA) safety committee (PRAC) concluded that “unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).” In their report, PRAC reminded health care professionals and vaccine recipients to be aware of the possibility of “blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination.” PRAC reports that the blood clots occurred in the abdomen (splanchnic vein thrombosis), brain (cerebral venous sinus thrombosis or CVST), and arteries, in conjunction with low levels of blood platelets and at times with bleeding.
According to PRAC, “One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin (heparin induced thrombocytopenia, HIT).” New studies and revised protocols to ongoing clinical trials have been requested by safety officials.
An in-depth review of 24 cases of splanchnic vein thrombosis and 62 cases of cerebral venous sinus thrombosis reported to the EU drug safety database, EudraVigilance, as of March 22, 2021 was completed by the committee. Of these cases, 18 were reported as fatal. The committee, however, continues to recommend the vaccine, stating that “The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.”
Vaccine use has resumed in many countries; however, some countries have restricted use of the product to persons over the age of 60 or 65 years of age. As of April 19, 2021, the vaccine remained suspended in Cameroon, Norway, and Denmark. On April 14, 2021, Danish health officials announced that it was halting use of the vaccine after studies had noted that blood clots occurred at a rate of one in 40,000 people.
On July 13, 2021, AstraZeneca company officials reported that they were working on modifying their COVID-19 vaccine in an attempt to reduce or eliminate the risk of blood clots.
The AstraZeneca COVID-19 vaccine has also been linked to Guillain-Barré Syndrome (GBS). GBS, a serious neurological disorder where the body’s immune system attacks the peripheral nervous system, can cause muscle weakness, paralysis, and even death. On September 8, 2021, the EMA stated that GBS should be listed as a potential adverse event following vaccination. According to the EMA, as of July 31, 2021, 833 cases of GBS had been reported after AstraZeneca COVID-19 vaccination.
Inovio Pharmaceuticals INO-4800 DNA Vaccine
Gene-based vaccines, which include DNA and mRNA types, encode for a specific viral protein from a pathogen - such as the spike protein for the SARS-CoV-2 virus. DNA vaccines deliver pieces of DNA into the nucleus of human cells in ways that result in production of pathogen protein antigens that subsequently, stimulate the immune system to produce antibodies specific to the pathogen’s antigen without becoming infected by the pathogen that can cause the disease. Compared to traditional vaccines, nucleic acid (genetic) vaccines are less inexpensive and easier to manufacture because they consist only of DNA or RNA, which is taken up and translated into protein by host cells.
In early April 2020, Inovio pharmaceuticals began Phase 1 clinical trials of its experimental COVID-19 DNA vaccine, INO-4800. Inovio’s COVID-19 vaccine research has been funded by a $9 million grant from the Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and a $5 million grant from the Bill and Melinda Gates Foundation. It also has a partnership with Philadelphia’s Wistar Institute and Beijing Advaccine Biotechnology Co. in China to develop the vaccine in addition to a $11.9 million contract with the U.S. Department of Defense to provide the experimental DNA coronavirus vaccine for upcoming clinical trials and potential manufacturing of the vaccine for military personnel in the future.
Inovio’s INO-4800 vaccine injects a small piece of circular DNA, called a plasmid (pGX9501), that encodes for the entire length of the Spike glycoprotein of SARS-CoV-2 to provoke the vaccine recipient’s cells into producing antibodies. The biggest challenge for DNA/RNA vaccines is getting patients’ cells to accept the introduced genetic material. At this point, the most effective technique appears to be electroporation, which is the delivering short pulses of electrical current to the patient to open cell pores and allow the plasmids to enter. This vaccine, unlike many of its counterparts, is stable at room temperature for over a year.
On June 30, 2020, Inovio Pharmaceutical announced positive results from its Phase 1 clinical trials. In the initial trial, 40 healthy adults between 18 and 50 years of age were administered two vaccine doses four weeks apart. Participants received either a 1.0mg or 2.0mg dose administered using INOVIO's CELLECTRA® 2000 device – a device that delivers short pulses of electrical current to the patient in addition to the vaccine. The electricity creates temporary pores in a patient’s cell membranes and this process enables the DNA/RNA to enter.
According to company officials, all 10 reported adverse events were considered Grade 1 and involved localized injection site redness.
The World Health Organization (WHO) has acknowledged that gaps in scientific knowledge exists regarding DNA vaccines and that their immune responses are not fully understood.
Some of the outstanding questions about DNA vaccine safety include:
- chronic inflammation because the vaccine continually stimulates the immune system to produce antibodies;
- possible integration of plasmid DNA into the body’s host genome resulting in mutations;
- problems with DNA replication;
- triggering of autoimmune responses, and
- activation of cancer-causing genes.
INOVIO’s CELLECTRA® 2000 electroporation device is also associated with higher rates of injection site pain in comparison to standard injections. A small clinical trial that involved the injection of a sterile solution followed by the use of the CELLECTRA® 2000 device reported mild to moderate injection pain, tenderness, redness and swelling, involuntary muscle contractions and increases in serum creatine phosphokinase (CK). CK is an enzyme found in the brain, heart, skeletal muscle, and other tissues and an increase in levels is indicative of muscle damage in the body.
In late September 2020, the U.S. Food and Drug Administration (FDA) placed the INO-4800 experimental vaccine trials on partial hold and requested more information on the clinical trials and the device used to deliver the vaccine. While the Phase 3 clinical trials remain on hold as of December 9, 2020, the FDA has permitted Inovio to proceed with Phase 2 clinical trials. According to Inovio:
“The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose to confirm the more appropriate dose(s) for each of three age groups with high risks of infection (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The Phase 3 segment of the INNOVATE trial remains on partial clinical hold until INOVIO satisfactorily resolves the FDA's remaining questions related to the CELLECTRA® 2000 device that will be used to deliver INO-4800 directly into the skin. The company plans to resolve the remaining device questions during the conduct of Phase 2 segment and prior to the start of the Phase 3 segment of the trial.”
Inovio company officials report that they expect to provide regulators with the answers to any questions by the end of the second quarter of 2021. Vaccine trials, however, are progressing in China in partnership with Advaccine Biopharmaceuticals Suzhou Co Ltd.
In October 2020, it was reported that Inovio’s experimental COVID-19 vaccine neutralized SARS-CoV-2 viruses with the D614G mutation that had become globally dominate.
Inovio announced in November 2020 that their INNOVATE Phase 2/3 randomized, blinded, placebo-controlled safety and efficacy trial would be funded by the U.S. Department of Defense and by December of 2020 had published Phase 1 clinical trial data suggesting that the vaccine generated both humoral (neutralizing antibodies) and/or cellular responses in CD4 and CD8 T cells.
Novavax COVID-19 Vaccine
Maryland-based Novavax Inc, a biotechnology company which has never successfully delivered a product to market, has developed an experimental vaccine using recombinant nanoparticle technology. Referred to as a protein subunit vaccine, NVX‑CoV2373 contains Novavax’s patented saponin-based Matrix-M™ adjuvant designed to enhance the immune response and stimulate high levels of neutralizing antibodies.
Matrix-M1 contains nm (nanometers) of nanoparticles composed of Quillaja saponins, phospholipid and cholesterol. Quillaja saponins are chemical compounds extracted from the soapbox tree and are used as emulsifiers in food additives and beverages.
Phase 1/2 clinical trials involved 131 participants, with 83 administered the NVX-CoV2373 vaccine containing the Matrix-M1 adjuvant to help stimulate an immune response to produce a strong antibody response. Of the remaining trial participants, 25 were given the NVX-CoV2373 vaccine without the Matrix-M1 adjuvant and 23 participants were given a placebo of sterile 0.9 percent normal saline. Participant received two intramuscular injections in the deltoid muscle administered three weeks apart.
Trial participants were divided into five group: group A, group B, group C, group D and group E. The 23 participants in group A received two doses of the placebo; 25 participants in group B received 25-μg (microgram) doses of the NVX-CoV2373 vaccine without the Matrix-M1 adjuvant; 29 participants in group C received 5-μg doses of NVX-CoV2373 with Matrix-M1; 28 participants in group D received 25-μg doses of NVX-CoV2373 with Matrix-M1; and 26 participants in group E received a single 25-μg dose of NVX-CoV2373 with Matrix-M1 followed by a single dose of placebo.
According to the results of the clinical trial, two of the 83 participants (one each in groups D and E) suffered “severe adverse events” (fatigue, headache, and malaise) after the first dose. Two participants—one each in groups A and E—had “reactogenicity events” (malaise, fatigue, and tenderness). Following administration of the second dose, one participant in group D had a “severe local event” (tenderness) and eight participants—one or two in each group—had “severe systemic events.” The most common of these severe systemic events were fatigue and joint pain. One participant in group D developed a fever greater than 100 °F.
Phase 3 clinical trials of NVX-CoV2373 began in the United Kingdom in late September 2020. This trial, a randomized, placebo-controlled, observer-blinded trial, was expected to enroll up to 10,000 volunteers. Half of the volunteers would be administered two intramuscular doses of the experimental vaccine candidate 21 days apart, while the remaining participants would receive a placebo.
On November 9, 2020, Novavax received “fast track” status from the U.S. Food and Drug Administration. This designation permitted the company to submit clinical data to the FDA when it became available rather than waiting for all results to be collected.
In late January 2021, company officials reported that the experimental vaccine was 89.3 percent effective at protecting individuals from illness. This data was based on interim results of late-stage clinical trials conducted in the U.K. The vaccine, however, was found to be only 49.4 percent effective in South African clinical trials, where the B.1.351 variant was most predominant.
By February 2021 Novavax had secured a memorandum of understanding with Canada and Takeda Pharmaceutical Company Ltd. (Japan) to produce the vaccine, while the European Medicines Agency (EMA) started their rolling reviews of the experimental vaccine. As Phase 3 trials continued in the United States and the United Kingdom, Novavax had secured advance commitments and purchase agreements totally over 1.2 billion doses of NVX-CoV2373 with GAVI, The Vaccine Alliance (formerly the Global Alliance for Vaccines and Immunization); Switzerland; Australia; New Zealand; and Canada.
On March 1, 2021, Novavax released pre-peer reviewed research results on their experimental NVX-CoV2373 vaccine. The Phase 2 component of their Phase 1/2 trial was a randomized placebo controlled trial to identify dosing regimen for the vaccine and each study arm contained about 250 participants assigned to one of four vaccine groups or placebo. Vaccine arms received one or two intramuscular doses at 5-μg or 25-μg or placebo, 21 days apart. Subsequent to randomization, 45 percent of participants were 50 to 84 years of age, and side effects were reported as mild and lasted about three days, with intensification after the second dose with the higher dosage of the vaccine. The lower dose antibody response was reported as 100 percent for all age groups with neutralizing antibody rates exceeding those present in convalescent sera. The study concluded by stating that the two-dose regimen at the lower dose of 5-μg was suited for young and old alike and was highly protective.
Local adverse reactions after one dose 5-μg regimen included injection site tenderness and pain across all age groups and were more frequent in younger groups 18 to 59 years of age (48 and 59 percent, respectively) than older vaccine participants 60 to 84 years of age (27 and 38 percent, respectively), with one report of a grade 3 adverse event in the low dose group and most systemic adverse events being noted as similar to placebo.
Upon receipt of the second dose, reports of injection site tenderness and pain increased across all age groups and lasted a median of two days. Injection site tenderness and pain were reported in vaccine groups as 65 and 76 percent for the lower age group; and 46 and 55 percent for the older group, respectively. The most frequent systemic adverse events reported in both age groups following the second dose of vaccine were fatigue (36 and 43 percent, respectively); muscle pain (31 and 41 percent, respectively); headache (30 and 34 percent, respectively); and malaise (26 and 30 percent, respectively).
Of unsolicited adverse events reported, one low dose participant discontinued the trial due to urinary incontinence that was felt to be unrelated to the vaccine. Serious adverse events in vaccine recipients included one case of acute colitis (considered vaccine related); one case of atrial fibrillation (unrelated, due to underlying heart disease); one case of vertigo (unrelated); and one case of non-Hodgkin’s lymphoma (unrelated).
In August 2021, Novavax company officials announced that they were seeking emergency use authorization in India, Indonesia, and the Philippines. They also reported that they would be requesting review by the World Health Organization for inclusion in the COVAX global COVID-19 vaccine program.
In September 2021, Novavax company officials announced that it was initiating a Phase 1/2 study of a combination COVID-19-seasonal flu vaccine. The clinical trial will combine Novavax' recombinant protein-based NVX-CoV2373 COVID-19 vaccine and their NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single vaccine product.
Clinical trials will involve 640 healthy Australians between 50 and 70 years of age. Trial participants, however, must have previously been infected with SARS-CoV-2 or been vaccinated with an approved COVID-19 vaccine at least eight weeks prior to enrollment in the vaccine trial. Participants will be randomized to different cohorts to evaluate the safety and efficacy of different vaccine formulations and doses. Participants will receive two vaccine doses, spaced 56 days apart. Results from the clinical trial are expected to be available in the first part of 2022.
IMPORTANT NOTE: NVIC encourages you to become fully informed about covid-19 and the covid-19 vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
Updated October 20, 2021
1 Hui D. Epidemic and Emerging Coronavirus (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). Clin Chest Med March 2017; 38(1): 71-86.
2 U.S. Centers for Disease Control and Prevention. Outbreak of Pneumonia of Unknown Etiology (PUE) in Wuhan, China. In: Emergency Preparedness and Response. Jan. 8, 2020.
3 Bill & Melinda Gates Foundation. Bill & Melinda Gates Foundation Dedicates Additional Funding to the Novel Coronavirus Response. Feb. 5, 2020.
4 World Health Organization (WHO). World experts and funders set priorities for COVID-19 research. Feb. 12, 2020.
5 Fasher L. Trump administration outlines audacious plan to deliver ‘hundreds of millions’ of Covid-19 vaccine doses by end of 2020. STAT News May 15, 2020.
10 Rauch S, Jasny E, Schmidt KE, et al. New Vaccine Technologies to Combat Outbreak Situations. Front Immunol 2018; 9:1963.
12 Misra S. Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Indian J Sex Transm Dis AIDS July-December 2012; 33(2):131-134.
14 Branswell H, Herper M, Fasher L, et al. Operation Warp Speed promised to do the impossible. How far has it come? Stat News Sept. 8, 2020.
15 Weise E. FDA says a coronavirus vaccine would have to be at least 50% effective to be approved. USA Today July 1, 2020.
16 U.S. Food and Drug Administration. Emergency Use Authorization for Vaccines to Prevent COVID-19. July 26, 2021.
17 Doshi P. Will covid-19 vaccines safe lives? Current trials aren’t designed to tell us. BMJ October 2020; 371:m4037.
19 Haseltine WA. Covid-19 Vaccine Protocols Reveal That Trials Are Designed To Succeed. Forbes Sept. 23, 2020.
20 Haseltine WA. Covid-19 Vaccine Protocols Reveal That Trials Are Designed To Succeed. Forbes Sept. 23, 2020.
22 U.S. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Dec. 11, 2020.
23 U.S. Food and Drug Administration. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. Dec. 18, 2020.
24 Cross R. Will the coronavirus help mRNA and DNA vaccines prove their worth? Chemical and Engineering News Apr. 3, 2020.
27 Levine H. The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works. Johnson & Johnson Sept. 23, 2020.
28 Weintraub A. J&J COVID-19 vaccine candidate protects monkeys after single dose. Fierce Biotech July 30, 2020.
29 U.S. Food and Drug Administration. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. Feb. 27, 2021.
32 Hendler C, Wrangham T, Cáceres M. FDA Approves BioNTech’s Comirnaty. Pfizer COVID Shot Remains Experimental. The Vaccine Reaction Sept. 4, 2021.
33 Hendler C, Wrangham T, Cáceres M. FDA Approves BioNTech’s Comirnaty. Pfizer COVID Shot Remains Experimental. The Vaccine Reaction Sept. 4, 2021.
34 Fisher BL, Pebsworth V, Wrangham T, et al. NVIC letter – FDA RADM Hinton for Clarifications on FDA August 23, 2021 EUA Reissue Letter to Pfizer. National Vaccine Information Center Aug. 30, 2021.
36 Jenco M. CDC panel OKs COVID-19 vaccines; discusses myocarditis, boosters. AAP News Aug. 30, 2021.
38 Lardieri A. Pfizer Applies for Full FDA Approval of Coronavirus Vaccine. U.S. News and World Report May 7, 2021.
39 Iacobucci G. Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data. BMJ 2021; 374.
40 Shah A, Marks P, Hahn S. Ensuring the safety and effectiveness of a covid-19 vaccine. HealthAffairs Aug. 18, 2020.
41 U.S. Food and Drug Administration. August 23, 2021 Summary Basis for Regulatory Action – Comirnaty. Aug. 23, 2021.
42 U.S. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Dec. 11, 2020.
43 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. May 10, 2021.
44 U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine – Fact Sheet for Healthcare Providers Administering Vaccine. Sept. 24, 2021.
45 U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine – Fact Sheet for Healthcare Providers Administering Vaccine. Sept. 24, 2021.
46 U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine – Fact Sheet for Healthcare Providers Administering Vaccine. Sept. 24, 2021.
47 U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine – Fact Sheet for Healthcare Providers Administering Vaccine. Sept. 24, 2021.
48 U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions. Sept. 24, 2021.
49 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA. Dec. 10, 2020.
50 U.S. Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Storage and Handling Summary Aug. 24, 2021.
51 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine. Feb. 25, 2021.
52 U.S. Food and Drug Administration. FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available. May 19, 2021.
53 Cáceres B. Pfizer’s Experimental COVID-19 Vaccine 90 Percent Effective? The Vaccine Reaction Nov. 17, 2020.
54 U.S. Centers for Disease Control and Prevention. Patient counseling. In: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Sept 27, 2021.
55 Joseph A Pfizer-BioNTech Covid-19 vaccine works just as well against variant first detected in U.K., study indicates. STAT News Jan. 20, 2021.
56 Kelland K. Study Suggests Pfizer's COVID-19 Vaccine Less Effective Against South African Variant Reuters Feb. 3, 2021.
57 McNamara D. Pfizer to Seek OK for COVID Vaccine Booster Targeting Delta. WebMD July 8, 2021.
58 Lovelace Jr. B. Israel says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness. CNBC July 23, 2021.
59 Stieber Z. Effectiveness of Some COVID-19 Vaccines Has Dropped Significantly: Study. The Epoch Times Aug. 12, 2021.
60 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. Aug. 12, 2021.
61 Schnirring L. FDA advisors OK Pfizer COVID booster for seniors, high-risk groups. CIDRAP News Sept. 17, 2021.
62 Soucheray S. FDA signals apprehension about COVID-19 vaccine booster shots. CIDRAP News Sept. 16, 2021.
63 U.S. Food and Drug Administration. FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations. Sept. 22, 2021.
64 Goodman B. CDC Chief Overrules Panel, OKs Boosters for Healthcare Workers. Medscape Sept. 23, 2021.
65 Dunleavy K. Biden administration's push for COVID boosters raises concerns about the science and morality of the plan. Fierce Pharma Aug. 19, 2021.
66 U.S. Food and Drug Administration. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine Dec. 18, 2020.
67 U.S. Food and Drug Administration. Moderna COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Aug. 31, 2021.
68 U.S. Food and Drug Administration. Moderna COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Aug. 31, 2021.
69 U.S. Food and Drug Administration. Moderna COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Aug. 31, 2021.
70 World Health Organization. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. Sept. 2, 2021.
71 U.S Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Presentation- FDA Review of Efficacy and Safety of Moderna COVID-19 Vaccine EUA. Dec. 17, 2020.
72 U.S. Centers for Disease Control and Prevention. Patient counseling. In: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Sept 27, 2021.
73 Joseph A. Moderna’s vaccine is less potent against one coronavirus variant but still protective, company says STAT News Jan. 25, 2021.
74 Stieber Z. Effectiveness of Some COVID-19 Vaccines Has Dropped Significantly: Study. The Epoch Times Aug. 12, 2021.
75 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. Aug. 12, 2021.
76 Pettypiece S, Strickler L. Moderna expected to miss Sept. 20 deadline for booster approval. NBC News Sept. 3, 2021.
78 Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine. development. Curr Opin Biotechnol 2007;18(6):546-556.
79 U.S. Food and Drug Administration. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. Feb. 27, 2021.
80 Johnson & Johnson. Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health and Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Mar. 20, 2020.
81 Levine H. The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works. Johnson & Johnson Sept. 23, 2020.
82 Weintraub A. J&J COVID-19 vaccine candidate protects monkeys after single dose. Fierce Biotech. July 30, 2020.
84 Raines K. Johnson & Johnson Pauses Phase 3 COVID-19 Vaccine Trial Following ‘Unexplained Illness’. The Vaccine Reaction Oct. 19, 2020.
85 Raines K. Johnson & Johnson Pauses Phase 3 COVID-19 Vaccine Trial Following ‘Unexplained Illness’. The Vaccine Reaction Oct. 19, 2020.
86 U.S Food and Drug Administration. Janssen COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Aug. 27, 2021.
87 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document- FDA. Feb. 26, 2021.
88 Schnirring L. FDA panel recommends J&J COVID vaccine for emergency use. CIDRAP News Feb. 26, 2021.
89 U.S. Centers for Disease Control and Prevention. Patient counseling. In: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Sept. 27, 2021.
90 Soucheray S. US halts J&J COVID vaccine after reports of blood clots. CIDRAP News Apr. 13, 2021.
91 Soucheray S. ACIP opts to lift pause on Johnson & Johnson vaccine. CIDRAP News Apr. 23, 2021.
92 Lee M. Pause on Johnson & Johnson COVID-19 Vaccine Lifted: CDC Vaccine Advisory Committee. The Epoch Times Apr. 23, 2021.
93 Shimabukuro T. Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. U.S. Centers for Disease Control and Prevention May 12, 2021.
94 Lovelace Jr. B. J&J, AstraZeneca explore modifying Covid vaccines in response to rare blood clot issue. CNBC July 13, 2021.
95 U.S. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. In: COVID-19. Oct. 13, 2021.
97 U.S. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. In: COVID-19. Oct. 13, 2021.
98 Paton J, Lyu D, Lauerman J. China’s Vaccine Front-Runner Aims to Beat Covid the Old-Fashioned Way. Bloomberg Businessweek Aug. 24, 2020.
99 Gan N. China is doubling down in the global push for a coronavirus vaccine. CNN Oct. 9, 2020.
102 Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine. development. Curr Opin Biotechnol 2007; 18(6):546-556.
104 TVR Staff. Oxford Begins COVID-19 Vaccine Trials to Meet September Deadline. The Vaccine Reaction Apr. 27, 2020.
105 Folegatti PM., Ewer KJ., et.al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS CoV-2: a preliminary report of a phase 1/2 single-blind, randomized, controlled trial. The Lancet August 2020; 396(10249):467-478.
106 Folegatti PM., Ewer KJ., et.al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS CoV-2: a preliminary report of a phase 1/2 single-blind, randomized, controlled trial. The Lancet August 2020; 396(10249):467-478.
107 Cáceres B. AstraZeneca Halts, Resumes COVID-19 Vaccine Trial After Serious Neurological Event. The Vaccine Reaction Sept. 14, 2020.
108 Cáceres B. AstraZeneca Halts, Resumes COVID-19 Vaccine Trial After Serious Neurological Event. The Vaccine Reaction Sept. 14, 2020.
109 Reuters. AstraZeneca's Japanese COVID-19 vaccine trial back up, U.S. still paused. MSN Oct. 2, 2020.
110 Scherer S. Canada joins countries in real-time AstraZeneca COVID vaccine review. Yahoo News Oct. 2, 2020.
111 Burton TM., Loftus P. Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resuming. The Wall Street Journal Oct. 23, 2020.
112 Reuters. COVID-19 vaccine roll-out expected in less than 3 months in UK: The Times. Yahoo News Oct. 2, 2020.
113 Reuters. AstraZeneca's Japanese COVID-19 vaccine trial back up, U.S. still paused. MSN Oct. 2, 2020.
114 Burton TM., Loftus P. Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resuming. The Wall Street Journal Oct. 23, 2020.
115 Villafana T. ACIP Presentation: AstraZeneca COVID-19 vaccine (AZD1222). U.S. Centers for Disease Control & Prevention Jan. 27, 2021.
116 Villafana T. ACIP Presentation: AstraZeneca COVID-19 vaccine (AZD1222). U.S. Centers for Disease Control & Prevention Jan. 27, 2021.
117 Burger L, Aripaka P. European regulator gives green light for Astra-Oxford COVID-19 vaccine. Reuters Jan. 29, 2021.
118 Hendler C. AstraZeneca’s COVID-19 Vaccine Not Recommended for People Over 65 in Germany. The Vaccine Reaction Feb. 7, 2021.
119 Cohen J. South Africa suspends use of AstraZeneca’s COVID-19 vaccine after it fails to clearly stop virus variant. Science Feb. 8, 2021.
121 Picheta R. AstraZeneca says “no evidence” of bloodclot risk from vaccine as countries suspend its use. CNN March 12, 2021.
122 TVR Staff. Italy Suspends AstraZeneca’s COVID Vaccine After Teen’s Brain Hemorrhage Death. The Vaccine Reaction June 14, 2021.
123 World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine. Mar. 19, 2021.
124 Ljunggren D, Martell A. Canada pauses AstraZeneca COVID-19 vaccine use for those under 55, wants new risk analysis. Reuters Mar. 29, 2021.
125 Halasz S, Isaac L, Kappeler I, Woodyatt A. Germany will limit AstraZeneca vaccine to people over 60. CNN Mar. 30, 2021.
126 European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Apr. 7, 2021.
127 European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Apr. 7, 2021.
128 European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Apr. 7, 2021.
129 Reuters. Factbox-Some Countries Limit AstraZeneca Vaccine Use, U.S. Pauses J&J Shot. U.S. News & World Reports Apr. 19, 2021.
130 AstraZeneca vaccine: Denmark stops rollout completely. BBC News Apr. 14, 2021.
131 Lovelace Jr. B. J&J, AstraZeneca explore modifying Covid vaccines in response to rare blood clot issue. CNBC July 13, 2021.
132 European Medicines Agency. COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB. Sept. 8, 2021.
133 Fisher BL Raines K. Inovio COVID-19 Vaccine Uses Electricity to Drive DNA Into Body Cells. The Vaccine Reaction Apr. 18, 2020.
134 Fisher BL, Raines K. Inovio COVID-19 Vaccine Uses Electricity to Drive DNA Into Body Cells. The Vaccine Reaction Apr. 18, 2020.
136 Fisher BL., Raines K. Inovio COVID-19 Vaccine Uses Electricity to Drive DNA Into Body Cells. The Vaccine Reaction Apr. 18, 2020.
138 INOVIO. Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19. June 30, 2020.
139 Fisher BL., Raines K. Inovio COVID-19 Vaccine Uses Electricity to Drive DNA Into Body Cells. The Vaccine Reaction Apr. 18, 2020.
140 INOVIO. Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19. June 30, 2020.
142 Zhang A. DNA Vaccines: Scientific and Ethical Barriers to the Vaccines of the Future. Harvard College Global Health Review. Nov. 15, 2011.
143 Fisher BL. Raines K. Inovio COVID-19 Vaccine Uses Electricity to Drive DNA Into Body Cells. The Vaccine Reaction Apr. 18, 2020.
144 Clinical Trials. FDA places partial hold on Inovio’s Phase II/III Covid-19 vaccine trial. Sept. 29, 2020.
145 INOVIO. INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense. Nov. 16, 2020.
146 Roy M. Inovio expects to begin late-stage COVID-19 vaccine study in second quarter. Reuters Jan. 4, 2021.
147 McAuley AJ, Kuiper MJ, Durr PA, et al. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. npj Vaccines October 2020; 5: 96.
148 Tebas P, Yang SP, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. January 2021; 31: 100689.
149 Carchidi A. Does Novavax Have What It Takes to Win the COVID-19 Vaccine Race? The Motley Fool May 24, 2020.
150 Goldman MC. Novavax Gains Following Promising Covid-19 Vaccine Trials. The Street Sept. 3, 2020.
151 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
152 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
153 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
154 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
155 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
156 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
157 Clinical Trials. Novavax launches Phase III trial of Covid-19 vaccine in UK. Sept. 25, 2020.
158 Manskar N Novavax COVID vaccine gets ‘fast track’ status from FDA. New York Post. Nov. 9, 2020.
159 Loftus P. Novavax Vaccine Is 89% Effective Against Covid-19 in U.K. Study. The Wall Street Journal Jan. 28, 2021.
160 Novavax. Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada. Feb. 2, 2021.
161 Takeda. Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan. Aug. 7, 2020.
162 European Medicines Agency. EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373). Mar. 2, 2021.
164 Novavax. Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine. Feb. 3, 2021.
165 Novavax. Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine. Jan. 07, 2021.
166 Novavax. Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine. Dec. 16, 2020.
167 Novavax. Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine. Jan. 22, 2021.
168 Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. medRxiv Mar. 1, 2021.
169 Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. medRxiv Mar. 1, 2021.
170 Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. medRxiv Mar. 1, 2021.
171 Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. medRxiv Mar. 1, 2021.
172 Neergaard L. Novavax seeks OK for COVID vaccine in needy countries first. Yahoo News Aug. 5, 2021.